A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH 0144471 on C3 Levels in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
- Conditions
- C3 glomerulopathiesdisease of the complement systemkidney disease1002766510029149
- Registration Number
- NL-OMON46833
- Lead Sponsor
- Achillion Pharmaceuticals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 5
Each patient must meet all of the following criteria to be enrolled in this study:
1. Must be between the ages of 16 and 65 years, inclusive
2. Must have a clinical diagnosis of C3G (C3 glomerulonephritis [C3GN] or dense deposit disease [DDD], the 2 types of C3G) or idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN) by renal biopsy for at least 3 months prior to dosing, with the pathologic diagnosis verified by review of the renal biopsy by the study central pathologist
3. C3 must be <50% of the lower limit of normal (LLN)
4. C4 must be >90% of the LLN
5. Female patients of childbearing potential must either agree to abstinence or to use two effective methods of contraception as defined in Section 5.5.5 from screening through 3 months after the last dose of ACH 0144471. Females who are of non-childbearing potential as defined in Section 5.5.5 need not employ a method of contraception.
6. Male patients must either agree to abstinence or to use two effective methods of contraception as defined in Section 5.5.5 throughout the dosing period and for at least 3 months after the last dose of ACH 0144471. Males who are surgically sterile need not employ additional contraception. Males must agree to not donate sperm throughout the dosing period and for at least 3 months following the last dose of ACH 0144471.
7. Must be capable of providing written informed consent, must be willing and able to comply with the requirements and restrictions listed in the consent form and with the visit schedule, treatment plan, laboratory tests, pharmacokinetic sampling schedule, and other study procedures, and must be willing and able to return for all study visits
8. Must be up-to-date on routine vaccinations, or be willing to be brought up-to-date, based on local guidelines
9. Must be willing to comply with study-specific vaccination requirements for Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis strains A, C, W, and Y
10. Must be willing, at all times for the duration of study participation, to have transportation and telephone access, and to be within one hour of an emergency medical center
Patients who meet any of the following criteria will be excluded from the study:
1. History of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant. Individuals receiving renal replacement therapy are also excluded
2. History or presence of any clinically relevant co-morbidities that would make the patient inappropriate for the study (for example, is likely to result in deterioration of the patient*s condition, affect the patient*s safety during the study, or confound the results of the study), in the opinion of the Principal Investigator
3. Evidence of monoclonal gammopathy of unclear significance (MGUS), infections, malignancy, autoimmune diseases, or other conditions to which C3 glomerulopathy or IC-MPGN may be secondary
4. Patients with other renal diseases that would interfere with interpretation of the study
5. Presence or evidence of hepatobiliary cholestasis
6. Known Gilbert*s syndrome and/or patients with a history suggestive of Gilbert*s syndrome
7. Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration, or patients with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration
8. Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 at the time of screening or at any time over the preceding four-weeks
9. History of febrile illness, a body temperature >38°C, or other evidence of a clinically significant active infection, within 14 days prior to study drug administration
10. Patients with evidence of human immunodeficiency virus, hepatitis B or hepatitis C infection (positive serology for HIV-1 antibody, positive hepatitis B surface antigen, or positive anti-HCV antibody at Screening or historically)
11. History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection
12. Contraindication to one or more of the required vaccinations
13. History of hypersensitivity reactions to commonly used antibacterial agents, including beta-lactams, penicillin, aminopenicillins, fluoroquinolones, cephalosporins, and carbapenems, which, in the opinion of the investigator and/or an appropriately qualified immunology or infectious disease expert, would make it difficult to properly provide either empiric antibiotic therapy or treat an active infection
14. Participation in a clinical study in which an investigational drug was given within 30 days, or within 5 half-lives of the investigational drug, whichever is longer, prior to study drug administration
15. Receipt of eculizumab at any dose or interval within the past 75 days prior to dosing
16. Use of tacrolimus or cyclosporine within 2 weeks of the first dose of ACH 0144471
17. 12-lead electrocardiogram with a QTcF >500 msec or findings which, in the opinion of the PI, could put the patient at undue risk
18. Any of the following laboratory abnormalities at screening:
* Alanine transaminase > ULN
* Aspartate aminotransferase > ULN
* Alkaline phosphatase > ULN
* Absolute neutrophil counts <1,000/*L
* Total bilirubin >1.5× ULN
* Indirect bilirubin > ULN
* Any laboratory abnormality that, in the opinion of the PI, would make the patient inappropriate for the study, or put the patient at undue risk
19. Donation of blood or
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>* Increase in C3 levels relative to baseline</p><br>
- Secondary Outcome Measures
Name Time Method <p>* The incidence of AEs, SAEs, and discontinuations due to AEs<br /><br>* Time (in days) to achieving peak C3 levels from the first day of dosing<br /><br>* The pharmacokinetic (PK) profiles of ACH 0144471 following the administration<br /><br>of multiple oral doses, and in the setting of dose taper<br /><br>* Changes in biomarkers of alternative pathway activity (AP) relative to<br /><br>baseline<br /><br>* The relationship between ACH 0144471 pharmacokinetics and changes in C3<br /><br>levels, and inhibition of alternative pathway activity (PK/PD)<br /><br><br /><br>Exploratory endpoints:<br /><br>* Patients* experience of their disease (C3G or IC-MPGN), its impact, and its<br /><br>management on everyday lives, from first symptoms to definitive diagnosis and<br /><br>beyond<br /><br>* Patients* expectations of ACH 0144471 in the treatment of their disease</p><br>